Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.41 |
| ▸ | HTR2B | P41595 | 8/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3552131 | 0.99 | HTR6 (0.41) | HTR6HTR2BHRH3DRD2HTR2C | |
| SCHEMBL3546437 | 0.95 | HRH3 (0.43) | HTR6HTR2BHRH3DRD2HTR2C | |
| Hydrochloric Acid SCHEMBL3548809 | 0.94 | HRH3 (0.42) | HTR6HTR2BHRH3DRD2HTR2C | |
| SCHEMBL3543253 | 0.89 | HTR6 (0.47) | HTR6HTR2BDRD2HTR2CFPR2 | |
| Hydrochloric Acid SCHEMBL3551150 | 0.88 | HTR6 (0.47) | HTR6HTR2BDRD2HTR2CFPR2 | |
| SCHEMBL3554575 | 0.88 | HTR6 (0.50) | HTR6HTR2BHRH3DRD2HTR2C | |
| Hydrochloric Acid SCHEMBL3549322 | 0.87 | HTR6 (0.49) | HTR6HTR2BHRH3DRD2HTR2C | |
| SCHEMBL3554271 | 0.86 | PARP1 (0.43) | HTR6HTR2BHRH3DRD2FPR2 | |
| Hydrochloric Acid SCHEMBL3555794 | 0.85 | PARP1 (0.43) | HTR6HTR2BHRH3DRD2FPR2 | |
| SCHEMBL3551850 | 0.84 | HTR6 (0.42) | HTR6HTR2BHRH3DRD2FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915348-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007032833-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-03-22 | — | — | WO | claimed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | claimed |
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2007032833-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | HTR6, HTR1A, HTR3B | HTR6 1/4885HTR2B 16/4885HRH3 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.